Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Conjugation of an scFab domain to the oligomeric HIV envelope protein for use in immune targeting.

King HAD, Gonelli CA, Tullett KM, Lahoud MH, Purcell DFJ, Drummer HE, Poumbourios P, Center RJ.

PLoS One. 2019 Aug 20;14(8):e0220986. doi: 10.1371/journal.pone.0220986. eCollection 2019.

2.

Boosting of Markers of Fcγ Receptor Function in Anti-HIV Antibodies During Structured Treatment Interruption.

Billings H, Wines BD, Dyer WB, Center RJ, Trist HM, Kent SJ, Hogarth PM.

AIDS Res Hum Retroviruses. 2019 Sep;35(9):842-852. doi: 10.1089/AID.2019.0047. Epub 2019 Aug 21.

3.

HIV-1-based Virus-like Particles that Morphologically Resemble Mature, Infectious HIV-1 Virions.

Gonelli CA, Khoury G, Center RJ, Purcell DFJ.

Viruses. 2019 Jun 2;11(6). pii: E507. doi: 10.3390/v11060507.

4.

Identification of Native and Posttranslationally Modified HLA-B*57:01-Restricted HIV Envelope Derived Epitopes Using Immunoproteomics.

Ramarathinam SH, Gras S, Alcantara S, Yeung AWS, Mifsud NA, Sonza S, Illing PT, Glaros EN, Center RJ, Thomas SR, Kent SJ, Ternette N, Purcell DFJ, Rossjohn J, Purcell AW.

Proteomics. 2018 Jun;18(12):e1700253. doi: 10.1002/pmic.201700253. Epub 2018 Apr 10.

PMID:
29437277
5.

Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection.

Parsons MS, Lloyd SB, Lee WS, Kristensen AB, Amarasena T, Center RJ, Keele BF, Lifson JD, LaBranche CC, Montefiori D, Wines BD, Hogarth PM, Swiderek KM, Venturi V, Davenport MP, Kent SJ.

Sci Transl Med. 2017 Aug 9;9(402). pii: eaaf1483. doi: 10.1126/scitranslmed.aaf1483.

PMID:
28794282
6.

HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV.

Madhavi V, Wines BD, Amin J, Emery S; ENCORE1 Study Group, Lopez E, Kelleher A; Sydney LTNP Study Group, Center RJ, Hogarth PM, Chung AW, Kent SJ, Stratov I.

J Virol. 2017 Aug 24;91(18). pii: e00700-17. doi: 10.1128/JVI.00700-17. Print 2017 Sep 15.

7.

Memory B Cells, the HLA-B*57 Allele and Natural Control of HIV Infection.

Center RJ.

EBioMedicine. 2017 Jul;21:47-48. doi: 10.1016/j.ebiom.2017.06.008. Epub 2017 Jun 13. No abstract available.

8.

Differentiating founder and chronic HIV envelope sequences.

Murray JM, Maher S, Mota T, Suzuki K, Kelleher AD, Center RJ, Purcell D.

PLoS One. 2017 Feb 10;12(2):e0171572. doi: 10.1371/journal.pone.0171572. eCollection 2017.

9.

The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs.

Vietheer PT, Boo I, Gu J, McCaffrey K, Edwards S, Owczarek C, Hardy MP, Fabri L, Center RJ, Poumbourios P, Drummer HE.

Hepatology. 2017 Apr;65(4):1117-1131. doi: 10.1002/hep.28989. Epub 2017 Feb 14.

10.

Trimeric gp120-specific bovine monoclonal antibodies require cysteine and aromatic residues in CDRH3 for high affinity binding to HIV Env.

Heydarchi B, Center RJ, Bebbington J, Cuthbertson J, Gonelli C, Khoury G, Mackenzie C, Lichtfuss M, Rawlin G, Muller B, Purcell D.

MAbs. 2017 Apr;9(3):550-566. doi: 10.1080/19420862.2016.1270491. Epub 2016 Dec 20.

11.

Repeated Vaccination of Cows with HIV Env gp140 during Subsequent Pregnancies Elicits and Sustains an Enduring Strong Env-Binding and Neutralising Antibody Response.

Heydarchi B, Center RJ, Gonelli C, Muller B, Mackenzie C, Khoury G, Lichtfuss M, Rawlin G, Purcell DF.

PLoS One. 2016 Jun 14;11(6):e0157353. doi: 10.1371/journal.pone.0157353. eCollection 2016.

12.

Brief Report: Seminal Plasma Anti-HIV Antibodies Trigger Antibody-dependent Cellular Cytotoxicity: Implications for HIV Transmission.

Parsons MS, Madhavi V, Ana-Sosa-Batiz F, Center RJ, Wilson KM, Bunupuradah T, Ruxrungtham K, Kent SJ.

J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):17-23. doi: 10.1097/QAI.0000000000000804.

PMID:
26761269
13.

Functional advantage of educated KIR2DL1(+) natural killer cells for anti-HIV-1 antibody-dependent activation.

Gooneratne SL, Center RJ, Kent SJ, Parsons MS.

Clin Exp Immunol. 2016 Apr;184(1):101-9. doi: 10.1111/cei.12752. Epub 2016 Feb 4.

14.

Role of education and differentiation in determining the potential of natural killer cells to respond to antibody-dependent stimulation.

Parsons MS, Loh L, Gooneratne S, Center RJ, Kent SJ.

AIDS. 2014 Nov 28;28(18):2781-6. doi: 10.1097/QAD.0000000000000489.

PMID:
25493604
15.

Antibody-dependent effector functions against HIV decline in subjects receiving antiretroviral therapy.

Madhavi V, Ana-Sosa-Batiz FE, Jegaskanda S, Center RJ, Winnall WR, Parsons MS, Ananworanich J, Cooper DA, Kelleher AD, Hsu D, Pett S, Stratov I, Kramski M, Kent SJ.

J Infect Dis. 2015 Feb 15;211(4):529-38. doi: 10.1093/infdis/jiu486. Epub 2014 Aug 28.

PMID:
25170105
16.

Inhibition of two temporal phases of HIV-1 transfer from primary Langerhans cells to T cells: the role of langerin.

Nasr N, Lai J, Botting RA, Mercier SK, Harman AN, Kim M, Turville S, Center RJ, Domagala T, Gorry PR, Olbourne N, Cunningham AL.

J Immunol. 2014 Sep 1;193(5):2554-64. doi: 10.4049/jimmunol.1400630. Epub 2014 Jul 28.

17.

Breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity: relevance to global HIV vaccine design.

Madhavi V, Wren LH, Center RJ, Gonelli C, Winnall WR, Parsons MS, Kramski M, Kent SJ, Stratov I.

AIDS. 2014 Aug 24;28(13):1859-70. doi: 10.1097/QAD.0000000000000310.

PMID:
24937308
18.

HIV-specific antibody-dependent phagocytosis matures during HIV infection.

Ana-Sosa-Batiz F, Johnston AP, Liu H, Center RJ, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Kim JH, Michael NL, Kelleher AD, Stratov I, Kent SJ, Kramski M.

Immunol Cell Biol. 2014 Sep;92(8):679-87. doi: 10.1038/icb.2014.42. Epub 2014 Jun 10.

PMID:
24913323
19.

The maturation of antibody technology for the HIV epidemic.

Winnall WR, Beasley MD, Center RJ, Parsons MS, Kiefel BR, Kent SJ.

Immunol Cell Biol. 2014 Aug;92(7):570-7. doi: 10.1038/icb.2014.35. Epub 2014 May 6. Review.

PMID:
24797582
20.

Anti-HIV antibody-dependent activation of NK cells impairs NKp46 expression.

Parsons MS, Tang CC, Jegaskanda S, Center RJ, Brooks AG, Stratov I, Kent SJ.

J Immunol. 2014 Jan 1;192(1):308-15. doi: 10.4049/jimmunol.1301247. Epub 2013 Dec 6.

21.

Utility of the Sindbis replicon system as an Env-targeted HIV vaccine.

Center RJ, Miller A, Wheatley AK, Campbell SM, Siebentritt C, Purcell DF.

Vaccine. 2013 Apr 26;31(18):2260-6. doi: 10.1016/j.vaccine.2013.02.064. Epub 2013 Mar 13.

PMID:
23499600
22.

Isotype-switched immunoglobulin G antibodies to HIV Gag proteins may provide alternative or additional immune responses to 'protective' human leukocyte antigen-B alleles in HIV controllers.

French MA, Center RJ, Wilson KM, Fleyfel I, Fernandez S, Schorcht A, Stratov I, Kramski M, Kent SJ, Kelleher AD.

AIDS. 2013 Feb 20;27(4):519-28. doi: 10.1097/QAD.0b013e32835cb720.

23.

Short communication: antibody responses to human immunodeficiency virus envelope from infections with multiple subtypes utilize the 1F7-idiotypic repertoire.

Parsons MS, Center RJ, Routy JP, Rouleau D, Leblanc R, Wainberg MA, Tremblay CL, Zannou MD, Kent SJ, Grant MD, Bernard NF.

AIDS Res Hum Retroviruses. 2013 May;29(5):778-83. doi: 10.1089/AID.2012.0094. Epub 2013 Jan 29.

24.

Role of monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity.

Kramski M, Schorcht A, Johnston AP, Lichtfuss GF, Jegaskanda S, De Rose R, Stratov I, Kelleher AD, French MA, Center RJ, Jaworowski A, Kent SJ.

J Immunol Methods. 2012 Oct 31;384(1-2):51-61. doi: 10.1016/j.jim.2012.07.006. Epub 2012 Jul 24.

PMID:
22841577
25.

Application of a case-control study design to investigate genotypic signatures of HIV-1 transmission.

Mota TM, Murray JM, Center RJ, Purcell DF, McCaw JM.

Retrovirology. 2012 Jun 25;9:54. doi: 10.1186/1742-4690-9-54.

26.

Anti-HIV-1 antibody-dependent cellular cytotoxicity mediated by hyperimmune bovine colostrum IgG.

Kramski M, Lichtfuss GF, Navis M, Isitman G, Wren L, Rawlin G, Center RJ, Jaworowski A, Kent SJ, Purcell DF.

Eur J Immunol. 2012 Oct;42(10):2771-81. doi: 10.1002/eji.201242469. Epub 2012 Aug 28.

27.

Influence of cytokines on HIV-specific antibody-dependent cellular cytotoxicity activation profile of natural killer cells.

Wren L, Parsons MS, Isitman G, Center RJ, Kelleher AD, Stratov I, Bernard NF, Kent SJ.

PLoS One. 2012;7(6):e38580. doi: 10.1371/journal.pone.0038580. Epub 2012 Jun 11.

28.

Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides.

Kramski M, Center RJ, Wheatley AK, Jacobson JC, Alexander MR, Rawlin G, Purcell DF.

Antimicrob Agents Chemother. 2012 Aug;56(8):4310-9. doi: 10.1128/AAC.00453-12. Epub 2012 Jun 4.

29.

NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients.

Johansson SE, Rollman E, Chung AW, Center RJ, Hejdeman B, Stratov I, Hinkula J, Wahren B, Kärre K, Kent SJ, Berg L.

Viral Immunol. 2011 Oct;24(5):359-68. doi: 10.1089/vim.2011.0025. Epub 2011 Sep 29.

PMID:
21958370
30.

Novel sensitive real-time PCR for quantification of bacterial 16S rRNA genes in plasma of HIV-infected patients as a marker for microbial translocation.

Kramski M, Gaeguta AJ, Lichtfuss GF, Rajasuriar R, Crowe SM, French MA, Lewin SR, Center RJ, Purcell DF.

J Clin Microbiol. 2011 Oct;49(10):3691-3. doi: 10.1128/JCM.01018-11. Epub 2011 Aug 3.

31.

Induction of humoral and cellular immune responses against the HIV-1 envelope protein using γ-retroviral virus-like particles.

Kirkegaard T, Wheatley A, Melchjorsen J, Bahrami S, Pedersen FS, Center RJ, Purcell DF, Ostergaard L, Duch M, Tolstrup M.

Virol J. 2011 Aug 1;8:381. doi: 10.1186/1743-422X-8-381.

32.

Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure.

Chung AW, Isitman G, Navis M, Kramski M, Center RJ, Kent SJ, Stratov I.

Proc Natl Acad Sci U S A. 2011 May 3;108(18):7505-10. doi: 10.1073/pnas.1016048108. Epub 2011 Apr 18.

33.

Co-expression of miRNA targeting the expression of PERK, but not PKR, enhances cellular immunity from an HIV-1 Env DNA vaccine.

Wheatley AK, Kramski M, Alexander MR, Toe JG, Center RJ, Purcell DF.

PLoS One. 2011 Mar 25;6(3):e18225. doi: 10.1371/journal.pone.0018225.

34.

Disulfide bond that constrains the HIV-1 gp120 V3 domain is cleaved by thioredoxin.

Azimi I, Matthias LJ, Center RJ, Wong JW, Hogg PJ.

J Biol Chem. 2010 Dec 17;285(51):40072-80. doi: 10.1074/jbc.M110.185371. Epub 2010 Oct 13.

35.

Efficient transcription through an intron requires the binding of an Sm-type U1 snRNP with intact stem loop II to the splice donor.

Alexander MR, Wheatley AK, Center RJ, Purcell DF.

Nucleic Acids Res. 2010 May;38(9):3041-53. doi: 10.1093/nar/gkp1224. Epub 2010 Jan 13.

36.

Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens.

Center RJ, Wheatley AK, Campbell SM, Gaeguta AJ, Peut V, Alcantara S, Siebentritt C, Kent SJ, Purcell DF.

Vaccine. 2009 Nov 5;27(47):6605-12. doi: 10.1016/j.vaccine.2009.08.016. Epub 2009 Aug 25.

PMID:
19712773
37.

Balancing reversion of cytotoxic T-lymphocyte and neutralizing antibody escape mutations within human immunodeficiency virus type 1 Env upon transmission.

Peut V, Campbell S, Gaeguta A, Center RJ, Wilson K, Alcantara S, Fernandez CS, Purcell DF, Kent SJ.

J Virol. 2009 Sep;83(17):8986-92. doi: 10.1128/JVI.00599-09. Epub 2009 Jun 10.

38.

Rapid degranulation of NK cells following activation by HIV-specific antibodies.

Chung AW, Rollman E, Center RJ, Kent SJ, Stratov I.

J Immunol. 2009 Jan 15;182(2):1202-10.

39.

Sindbis virus vectors elicit hemagglutinin-specific humoral and cellular immune responses and offer a dose-sparing strategy for vaccination.

Miller A, Center RJ, Stambas J, Deliyannis G, Doherty PC, Howard JL, Turner SJ, Purcell DF.

Vaccine. 2008 Oct 16;26(44):5641-8. doi: 10.1016/j.vaccine.2008.07.102. Epub 2008 Aug 28.

PMID:
18761047
41.

Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface.

Center RJ, Leapman RD, Lebowitz J, Arthur LO, Earl PL, Moss B.

J Virol. 2002 Aug;76(15):7863-7.

42.

Oligomeric structure of virion-associated and soluble forms of the simian immunodeficiency virus envelope protein in the prefusion activated conformation.

Center RJ, Schuck P, Leapman RD, Arthur LO, Earl PL, Moss B, Lebowitz J.

Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):14877-82.

43.

Functional implications of the human T-lymphotropic virus type 1 transmembrane glycoprotein helical hairpin structure.

Maerz AL, Center RJ, Kemp BE, Kobe B, Poumbourios P.

J Virol. 2000 Jul;74(14):6614-21.

44.

Evolutionary conservation of the membrane fusion machine.

Poumbourios P, Center RJ, Wilson KA, Kemp BE, Kobe B.

IUBMB Life. 1999 Aug;48(2):151-6. Review.

45.

The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts.

Center RJ, Earl PL, Lebowitz J, Schuck P, Moss B.

J Virol. 2000 May;74(10):4448-55.

47.

Crystallization of a trimeric human T cell leukemia virus type 1 gp21 ectodomain fragment as a chimera with maltose-binding protein.

Center RJ, Kobe B, Wilson KA, Teh T, Howlett GJ, Kemp BE, Poumbourios P.

Protein Sci. 1998 Jul;7(7):1612-9.

48.
49.
50.

Identification of brain isoforms of the rat calcitonin receptor.

Sexton PM, Houssami S, Hilton JM, O'Keeffe LM, Center RJ, Gillespie MT, Darcy P, Findlay DM.

Mol Endocrinol. 1993 Jun;7(6):815-21.

PMID:
8395656

Supplemental Content

Loading ...
Support Center